AbbVie joins peers in Middle East with Saudi Arabia plans

AbbVie ($ABBV) is joining the rush to the Middle East with operations in Saudi Arabia. Its deal for the Arab Company for Pharmaceutical Products (Arabio) to manufacture Humira and other drugs in the kingdom is seen as a significant advance in the country's ability to manufacture biologics. AbbVie joins Pfizer ($PFE), which is building a plant there, while Sanofi ($SNY), Merck & Co. ($MRK) and others are establishing production and distribution operations throughout the Middle East. It is a region that is seen as one the emerging markets with the most potential. Story | More

Suggested Articles

In a high-stakes patent lawsuit between the CAR-T companies of Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.